Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

Cubist Pharmaceuticals logo

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CBST Stock News Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Key facts about Cubism
CBST:CA The Cannabist Company Holdings Inc.
What is Cubism?
Cubist Stock Hits New 52-Week High (CBST)
See More Headlines

CBST Stock Analysis - Frequently Asked Questions

Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. Cubist Pharmaceuticals's revenue for the quarter was up 16.2% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Bausch Health Cos (BHC), Booking (BKNG), BioMarin Pharmaceutical (BMRN), Bristol Myers Squibb (BMY) and FLEETCOR Technologies (FLT).

Company Calendar

Last Earnings
10/21/2014
Today
10/10/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBST
CIK
912183
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CBST) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners